I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

In a study published in the Journal of Cell Science, Eswarappa's team zeroed in on a gene that codes for a protein called FEM1B. They show how FEM1B mRNA readthrough plays a key role in the cell ...

a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. The company reported 67 percent overall response rate in target population, while the targeted response was 20 ...